Fungiscope - A Global Emerging Fungal Infection Registry

NCT01731353

Last updated date
Study Location
University Hospital Cologne
Cologne, NRW, 50937, Germany
Contact
+49 221 478

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+49 221 478

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Invasive Fungal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Cultural, histopathological, antigen, or DNA evidence of invasive fungal infection

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Infection due to Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis
jiroveci


- Endemic fungal infection such as coccidioidomycosis or histoplasmosis


- Colonisation or other non-invasive infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Invasive Fungal DiseaseFungiscope - A Global Emerging Fungal Infection Registry
NCT01731353
  1. Cologne, NRW
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Fungiscope - A Global Emerging Fungal Infection Registry
Official Title Fungiscope - A Global Emerging Fungal Infection Registry
Brief Summary The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.
Detailed Description

The specific objectives are:

  1. To determine the fungal species causing invasive fungal infection in different parts of the world.
  2. To determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis.
  3. To describe the therapeutic regimens used and their efficacy.
  4. To share clinical isolates among the contributors of Fungiscope.
  5. To develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
  • fixed tissue
  • fungal culture
Sampling Method Non-Probability Sample
Study Population Invasive infections caused by emerging fungi
Condition Invasive Fungal Disease
Intervention Not Provided
Study Groups/Cohorts Emerging fungal infections
Web-based registry of invasive infections by emerging fungi
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: November 15, 2012)
1000
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2021
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Cultural, histopathological, antigen, or DNA evidence of invasive fungal infection

Exclusion Criteria:

  • Infection due to Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci
  • Endemic fungal infection such as coccidioidomycosis or histoplasmosis
  • Colonisation or other non-invasive infection
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Oliver A Cornely, Prof.+49 221 478 ext 6494[email protected]
Listed Location Countries Germany
Removed Location Countries  
 
Administrative Information
NCT Number NCT01731353
Other Study ID Numbers Fungi001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Oliver Cornely, MD, University of Cologne
Study Sponsor University of Cologne
Collaborators
  • Astellas Pharma GmbH
  • Gilead Sciences
  • Merck Sharp & Dohme Corp.
  • Pfizer
  • Basilea Pharmaceutica
Investigators
Principal Investigator:Oliver A. Cornely, ProfessorUniversity Hospital of Cologne
PRS Account University of Cologne
Verification Date July 2016